2021年FDA安全警示后,行业财务关系与ADM研究结论的关联
该研究分析2020至2025年四本整形外科期刊中46项ADM临床研究,将结论编码为正面、中立或阴性,并结合Open Payments数据评估第一作者与资深作者收款情况。结果显示正面结论占比由警示前43.6%降至23.9%,但更高收款仍与正面报告相关(OR 1.37;p<0.001),与正面结论相关的财务阈值由376美元升至1,921美元。
要点
- FDA警示后ADM研究正面结论占比下降,但作者财务关系仍与正面报告相关。
- 正面研究作者收款中位数8,792美元,显著高于中立或阴性研究作者的0美元(p<0.001)。
- 与正面结论相关的财务阈值较警示前升高约五倍,解读ADM研究需关注行业关系及其规模。
核心结论
- FDA警示与正面ADM研究减少同时出现,但行业财务关系仍与有利报告相关,且无法证明付款导致单项研究结论。
研究设计与样本
- 分析2020至2025年四本整形外科期刊(沿用既往基准研究)发表的46项ADM临床研究,结论编码为正面、中立或阴性。
- 查询第一作者与资深作者的Open Payments数据,用逻辑回归与ROC分析评估付款与结论倾向的关联。
- 结果与2014至2019年警示前历史队列比较。
主要发现
- 46项研究中23.9%报告正面结论,低于警示前时代的43.6%。
- 正面研究作者收款中位数显著高于中立或阴性研究作者(8,792美元 vs. 0美元;p<0.001)。
- 回归显示较高付款与有利报告相关(OR 1.37;p<0.001)。
- 与正面结论相关的财务阈值由警示前376美元升至1,921美元,升高约五倍。
临床怎么用
- 审稿人、期刊与读者解读ADM研究时应同时考虑行业关系的存在与规模。
局限性
- 研究结果为关联性,不能确立付款与单项研究结论之间的因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Financial conflicts of interest may be associated with outcome reporting in surgery. In March 2021, the FDA issued a safety communication highlighting complications associated with acellular dermal matrices (ADM) in breast reconstruction. This study assessed whether the association between industry payments and favorable ADM reporting persisted after this regulatory intervention. METHODS: We analyzed clinical ADM studies published from 2020 to 2025 in the four plastic surgery journals used in the prior benchmark study. Conclusions were coded as positive, neutral, or negative. Open Payments data were queried for first and senior authors. Logistic regression and receiver operating characteristic (ROC) analysis determined the association between payments and favorability. Findings were compared with a historical pre-warning cohort (2014-2019). RESULTS: Of 46 studies, 23.9% reported positive conclusions, down from 43.6% in the pre-warning era. Despite this decline, financial ties remained associated with favorable reporting. Authors of positive studies received significantly higher median payments than authors of neutral or negative studies ($8,792 vs. $0; p < 0.001). Regression demonstrated an association between higher payments and favorable reporting (OR 1.37; p < 0.001). The financial threshold associated with positive conclusions rose five-fold, from $376 pre-warning to $1,921. CONCLUSIONS: Although the FDA warning coincided with fewer positive studies, financial relationships remained associated with favorable reporting. These findings are associative and do not establish that payments caused individual study conclusions. Reviewers, journals, and readers should consider both the presence and magnitude of industry relationships when interpreting ADM studies.
引用
- Sifil MK, Kahn DM. Does Industry Influence Persist? Financial Conflicts and ADM Outcomes After the 2021 FDA Safety Alert. Plast Reconstr Surg. 2026. PMID: 42606309. doi:10.1097/PRS.0000000000013381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。